Recludix Pharma
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3010 Science Park Rd 200, San Diego, Cal...Phone Number
(858) 258-5445Website
www.recludixpharma.comRevenue
$13.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About Recludix Pharma
Recludix Pharma focuses on unlocking new therapeutic possibilities to improve the lives of patients suffering from inflammatory diseases. The company specializes in the research and development of biologically-validated targets associated with SH2 domains, which play a critical role in cellular signaling and response. With a commitment to innovation, Recludix encourages collaboration and communication among team members to drive transformative advancements in medicine. Their mission is to develop groundbreaking treatments that address previously elusive targets in the field of inflammatory disorders.Explore more
Recludix Pharma Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Recludix Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Recludix Pharma is spiking on competitors!
Click to see if Recludix Pharma had a recent Job posting/layoffs
Recludix Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Recludix Pharma has new funding data
Product Launch: Get notified when Recludix Pharma launches new products
Check if Recludix Pharma has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Recludix Pharma
Earning: See what the market has to say on Recludix Pharma recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Recludix Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to Recludix Pharma
Compare insights from companies similar to Recludix Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Recludix Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Recludix Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Recludix Pharma.
Recludix Pharma Tech Stack
A closer look at the technologies used by Recludix Pharma
Most Recent Scoops
Promotion
Executive Move
Executive Moves, Promotion
Promotion
Executive Move
Executive Moves, Promotion
Funding
Funding
Open Position
Open Position
Recludix Pharma News & Media
Recludix Pharma to Present at RBC Capital Markets Global Healthcare Conference
SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the RBC Capital Markets Global Healthcare Conference in New York, NY. The company’s presentation will be on Wednesday, May 20, 2026, at 2:35 p.m. Eastern Time.Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways and Differentiated Safety Profile of Oral STAT6 Inhibitor REX-8756 (also known as SAR448755) in a Model of Atopic Dermatitis
- REX-8756 is an oral, first-in-class orthosteric STAT6 inhibitor currently being evaluated in an ongoing Phase 1 clinical study - REX-8756 is an oral, first-in-class orthosteric STAT6 inhibitor currently being evaluated in an ongoing Phase 1 clinical studyRecludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced preclinical data for STAT6 inhibitor REX-8756 and STAT1/3 inhibitors will be highlighted in two oral presentations at the Society for Investigative Dermatology (SID) Annual Meeting taking place May 13-16, 2026, in Chicago, IL. REX-8756 is an oral, potent and selective STAT6 inhibitor being evaluaRecludix Pharma Promotes Executive Leaders Following Recent Corporate Accomplishments
– Ajay Nirula, M.D., Ph.D., will now also serve as president, in addition to his role as head of research and development
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Recludix Pharma
Sign Up For FreeTo access detailed company insights
Recludix Pharma focuses on unlocking new therapeutic possibilities to improve the lives of patients suffering from inflammatory diseases. The company specializes in the research and development of biologically-validated targets associated with SH2 domains, which play a critical role in cellular signaling and response. With a commitment to innovatio... Read More
